Improved efficacy of tafasitamab plus lenalidomide versus systemic therapies for relapsed/refractory DLBCL: RE-MIND2, an observational retrospective matched cohort study Journal Article
| Authors: | Nowakowski, G. S.; Yoon, D. H.; Peters, A.; Mondello, P.; Joffe, E.; Fleury, I.; Greil, R.; Ku, M.; Marks, R.; Kim, K.; Zinzani, P. L.; Trotman, J.; Huang, D.; Waltl, E. E.; Winderlich, M.; Kurukulasuriya, N. C.; Ambarkhane, S.; Hess, G.; Salles, G. |
| Article Title: | Improved efficacy of tafasitamab plus lenalidomide versus systemic therapies for relapsed/refractory DLBCL: RE-MIND2, an observational retrospective matched cohort study |
| Abstract: | PURPOSE: In RE-MIND2 (NCT04697160), patient-level outcomes from the L-MIND study (NCT02399085) of tafasitamab plus lenalidomide were retrospectively compared with patient-level matched observational cohorts treated with National Cancer Care Network (NCCN)/European Society for Medical Oncology (ESMO)-listed systemic therapies for relapsed/refractory diffuse large B-cell lymphoma (DLBCL). PATIENTS AND METHODS: Data were collected from health records of eligible patients aged ≥18 years with histologically confirmed DLBCL who had received ≥2 systemic therapies for DLBCL (including ≥1 anti-CD20 therapy). Patients from L-MIND were matched with patients from the RE-MIND2 observational cohort using estimated propensity score-based 1:1 nearest-neighbor matching, balanced for nine covariates. The primary analysis compared tafasitamab plus lenalidomide with patients who received any systemic therapy for R/R DLBCL (pooled in one cohort) or bendamustine plus rituximab (BR) or rituximab plus gemcitabine and oxaliplatin (R-GemOx; as two distinct cohorts). The primary endpoint was overall survival (OS). Secondary endpoints included treatment response and time-to-event outcomes. RESULTS: In RE-MIND2, 3,454 patients were enrolled from 200 sites in North America, Europe, and Asia-Pacific. Strictly matched pairs of patients consisted of tafasitamab plus lenalidomide versus systemic therapies pooled (n = 76 pairs), versus BR (n = 75 pairs), and versus R-GemOx (n = 74 pairs). Significantly prolonged OS was reported with tafasitamab plus lenalidomide versus systemic pooled therapies [hazard ratios (HR): 0.55; P = 0.0068], BR (HR: 0.42; P < 0.0001), and R-GemOx (HR: 0.47; P = 0.0003). CONCLUSIONS: RE-MIND2, a retrospective observational study, met its primary endpoint, demonstrating prolonged OS with tafasitamab plus lenalidomide versus BR and R-GemOx. See related commentary by Cherng and Westin, p. 3908. ©2022 The Authors; Published by the American Association for Cancer Research. |
| Keywords: | adolescent; adult; treatment outcome; retrospective studies; lenalidomide; rituximab; antineoplastic agent; cohort studies; antineoplastic combined chemotherapy protocols; cohort analysis; bendamustine; pathology; retrospective study; monoclonal antibody; lymphoma, large b-cell, diffuse; oxaliplatin; diffuse large b cell lymphoma; antibodies, monoclonal, humanized; humans; human; bendamustine hydrochloride; tafasitamab |
| Journal Title: | Clinical Cancer Research |
| Volume: | 28 |
| Issue: | 18 |
| ISSN: | 1078-0432 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2022-09-15 |
| Start Page: | 4003 |
| End Page: | 4017 |
| Language: | English |
| DOI: | 10.1158/1078-0432.Ccr-21-3648 |
| PUBMED: | 35674661 |
| PROVIDER: | scopus |
| PMCID: | PMC9475241 |
| DOI/URL: | |
| Notes: | Editorial -- Export Date: 1 November 2022 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work